Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acute Liver Injury Clear all
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Completed No phase listed Observational

International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

NCT05387811
View directory record Official record
Conditions
Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
Combination Product
Lead sponsor
Azienda Ospedaliera di Padova
Other
Eligibility
18 Years and older
Enrollment
1,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 30, 2026, 10:25 AM EDT
Not listed Phase 2 Interventional

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

NCT05875948
View directory record Official record
Conditions
Hepatorenal Syndrome, Acute Kidney Injury
Interventions
R2R01, Terlipressin
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
7
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 30, 2026, 10:25 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant

NCT01619449
View directory record Official record
Conditions
Acute Kidney Injury, Liver Disease, Chronic Kidney Disease, End Stage Kidney Disease
Interventions
Renal replacement therapy
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated Phase 3 Interventional

INR-Triggered Transfusion In GI Bleeders From ER

NCT01461889
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Gastrointestinal Hemorrhage, Liver Diseases, Transfusion Related Lung Injury
Interventions
Transfuse plasma to High INR target, Transfuse plasma to Low INR target
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 30, 2026, 10:25 AM EDT
Not listed Phase 1 Interventional

Use of Direct Peritoneal Resuscitation in High-risk Liver Transplant Recipients

NCT05195125
View directory record Official record
Conditions
End Stage Liver DIsease, Obesity, Acute Kidney Injury
Interventions
Direct Peritoneal Resuscitation
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 30, 2026, 10:25 AM EDT
Completed No phase listed Observational

A Multi-Center Trial to Study Acute Liver Failure in Adults

NCT00518440
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Acute Liver Injury
Interventions
Not listed
Lead sponsor
William Lee
Other
Eligibility
18 Years and older
Enrollment
3,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2022 · Synced Oct 30, 2026, 10:25 AM EDT
Recruiting Not applicable Interventional

Initial Resuscitation for Acute Kidney Injury in Cirrhosis

NCT06525623
View directory record Official record
Conditions
Cirrhosis, Liver, Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Recommendation: No Further Resuscitation, Recommendation: Resuscitation with Crystalloid, Recommendation: Resuscitation with Colloid, Recommendation: Standard of Care IV Albumin
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury

NCT01548690
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury
Interventions
Ornithine Phenylacetate
Drug
Lead sponsor
William Lee
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 30, 2026, 10:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 1 Interventional

miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial

NCT06285253
View directory record Official record
Conditions
Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
Interventions
miroliverELAP treatment
Combination Product
Lead sponsor
Miromatrix Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 2 Interventional

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

NCT04563026
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
DUR-928 30 mg, DUR-928 90 mg, Placebo+ Standard of Care (SOC)
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 30, 2026, 10:25 AM EDT
Completed No phase listed Observational

Acute Liver Injury in Patients on Dapagliflozin

NCT02695095
View directory record Official record
Conditions
Acute Liver Injury
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
424,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 30, 2026, 10:25 AM EDT
Not listed Not applicable Interventional

Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study

NCT02147470
View directory record Official record
Conditions
Liver Cirrhosis and Acute Kidney Injury
Interventions
Definity ultrasound contrast agent
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 30, 2026, 10:25 AM EDT
Completed No phase listed Observational

Risk of Acute Liver Injury in Users of Antimicrobials

NCT01434173
View directory record Official record
Conditions
Drug-Induced Liver Injury
Interventions
Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,299,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Many Locations, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients

NCT06000748
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Portal Hypertension, Hepatorenal Syndrome, Acute Tubule Necrosis, Prerenal Failure
Interventions
MAP-Target Algorithm
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated No phase listed Observational

Predicting Lung Injury From Transfusion in Patients With Liver Disease

NCT01756690
View directory record Official record
Conditions
Transfusion-related Acute Lung Injury, Chronic Liver Disease, Gastrointestinal Bleeding
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated Phase 3 Interventional Results available

Everolimus Plus Mycophenolic Acid for Kidney Preservation in Liver Transplant Recipients With Impaired Kidney Function

NCT04258423
View directory record Official record
Conditions
Kidney Failure
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 30, 2026, 10:25 AM EDT
Withdrawn No phase listed Observational

Safety of Iodinated Contrast in Liver Transplant Candidates With Decreased Renal Function Undergoing Coronary CT Angiography

NCT03806725
View directory record Official record
Conditions
Acute Kidney Injury, Renal Insufficiency, Chronic, Contrast-induced Nephropathy, Liver Transplantation, Contrast Media
Interventions
Intravenous administration of iodinated contrast medium for coronary CT angiography
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 30, 2026, 10:25 AM EDT
Terminated Phase 2 Interventional

A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

NCT06987968
View directory record Official record
Conditions
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
Interventions
VS-01 on top of SOC (Active Treatment Group), SOC
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 79 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Completed Phase 2Phase 3 Interventional Results available

13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF

NCT02786836
View directory record Official record
Conditions
Acute Liver Failure
Interventions
13C-Methacetin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 30, 2026, 10:25 AM EDT
Suspended Not applicable Interventional

The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I

NCT04898010
View directory record Official record
Conditions
Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Selective Cytopheretic Device
Device
Lead sponsor
Lenar Yessayan
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Recruiting No phase listed Observational

Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients

NCT04937868
View directory record Official record
Conditions
Abdominal Injury, Pelvic Fracture, Genital Hemorrhage, Lumbar Spine Injury, Hip Injuries, Liver Injury, Spleen Injury, Renal Injury, Diaphragm Injury, Aortic Rupture, Aortic Dissection, Bowel Disease, Vascular System Injuries, Sacral Fracture
Interventions
There are no interventions associated with this study
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 30, 2026, 10:25 AM EDT
Recruiting Phase 2 Interventional

Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury

NCT06937307
View directory record Official record
Conditions
Acute Kidney Injury, Cirrhosis, Decompensated Cirrhosis of Liver
Interventions
Droxidopa capsules, Placebo
Drug · Other
Lead sponsor
Giuseppe Cullaro, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 10:25 AM EDT